LambdaTest Partners with LinkedIn to Offer Test Automation Professional Certificate on LinkedIn Learning
6.3.2023 19:00:00 EET | Business Wire | Press release
LambdaTest, the leading digital experience testing cloud platform, has partnered with LinkedIn to offer the LambdaTest Test Automation Professional Certificate exclusively available on LinkedIn Learning, as part of its mission to support the testing and QA community.
Through this Professional Certificate course, learners will acquire fundamental knowledge of test automation, including various tools and best practices, in a highly engaging manner from Meaghan Lewis, Technical Program Manager at Microsoft.
More importantly, learners will be able to implement and optimize test automation in their jobs after this course. To earn their LambdaTest Test Automation Professional Certificate, learners will have to complete all courses and content in the learning path and pass the final exam. Learners can access their certificates immediately after they pass the final exam and seamlessly showcase their certificate on LinkedIn.
"We are excited to partner with LambdaTest to provide our customers and learners additional, credible paths to upskilling as well as broaden the audience for the LambdaTest Test Automation Professional Certificate to the world’s largest talent marketplace," said Dan Brodnitz, Sr. Director of Global Content Strategy at LinkedIn Learning.
As LinkedIn Learning students for the LambdaTest Test Automation Professional Certificate, learners can get free trial access to the LambdaTest platform. This enables learners to get hands-on experience and implement the concepts.
“Enterprises, all over the world, are automating their testing to ensure a better digital experience for their users. Learning test automation will open up various career avenues for learners. We are also happy to offer free access to the LambdaTest platform to enable students to get hands-on experience. We are excited to play our role in enabling thousands of learners to achieve their career goals,” said Maneesh Sharma, Chief Operating Officer, LambdaTest.
LambdaTest recently announced the launch of digital experience testing cloud for enterprises. The offering will enable enterprises to accelerate their digital transformation by providing a best-in-class, 360-degree test execution and orchestration platform coupled with insightful test analytics and customizable deployment options.
Also, Satya Nadella, Chairman & CEO of Microsoft, delivered the keynote address at the Microsoft Future Ready Technology Summit 2023, Bengaluru, where he said that “LambdaTest is doing for test automation what Kubernetes did for container orchestration - creating that next level of efficiency around test automation so that people can actually focus on testing versus test orchestration.”
To know more, visit: https://www.lambdatest.com/certifications/linkedin-learning
Notes to the editor
For further information please contact the LambdaTest press office: press@lambdatest.com.
About LambdaTest
LambdaTest is a leading digital experience testing cloud that helps developers and testers ship code faster. Over 10,000+ enterprise customers and 2+ million users across 130+ countries rely on LambdaTest for their testing needs.
LambdaTest platform provides secure, scalable, and insightful test orchestration for customers at different points in their DevOps (CI/CD) lifecycle:
● Cross Browser Testing Cloud
LambdaTest test execution platform allows users to run both manual and automated tests across 3000+ different browsers, real devices, and operating system environments. It enables developers to test their websites, web applications, and native apps without requiring to install or maintain an internal lab of virtual machines, real devices, emulators, or simulators.
● Real Device Testing Cloud
With LambdaTest’s Real Devices Testing Cloud, you can now test unhandled errors, UI/UX, performance, and functionality of your native, web, and hybrid apps before they get released into production. Test on the widest range of mobile and OTT devices (iOS, Android, iPad, Amazon Fire TV, Roku TV & Apple TV). With seamless cross-functional team collaboration across the mobile app development lifecycle, you can release quality mobile apps in shorter development cycles which enables you to innovate and scale rapidly.
● Continuous Testing Cloud - HyperExecute
An IP-led next-gen cloud test execution and orchestration platform that helps enterprises run end-to-end automation tests at the fastest speed possible, thereby enabling them to achieve quicker time-to-market, and deliver a quality digital experience. Achieve 70% faster test execution times and zero flakiness with HyperExecute.
● Visual Regression cloud
Perform Regression Testing in just one click using LambdaTest. Compare the screenshots of your application’s webpages taken from two different browsers to view/detect any visual deviations. Increase browser coverage by running automation scripts on a cloud of 3000+ different desktop and mobile environments.
● Test Intelligence at Scale
Test execution insights are critical for digital transformation as they provide enterprises with more profound insight into the quality of releases and trends. By analyzing the test execution data, LambdaTest's Integrated Test Intelligence delivers enterprises with insights into patterns and trends that can lead to informed decisions about future development and improve application quality.
For more information, please visit: https://lambdatest.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005067/en/
Contact information
LambdaTest press office:
press@lambdatest.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom